- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- April 2026
- 285 Pages
Global
From €5243EUR$5,850USD£4,570GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- April 2026
- 179 Pages
Global
From €5243EUR$5,850USD£4,570GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,508GBP
- Report
- January 2026
- 182 Pages
Global
From €4033EUR$4,500USD£3,516GBP
- Report
- July 2025
- 350 Pages
Global
From €4435EUR$4,949USD£3,867GBP
- Report
- May 2025
- 80 Pages
Global
From €3500EUR$4,183USD£3,158GBP
- Report
- November 2023
- 130 Pages
Global
From €4033EUR$4,500USD£3,516GBP
- Report
- January 2023
- 130 Pages
Global
From €2016EUR$2,250USD£1,758GBP
- Report
- November 2024
- 110 Pages
Global
From €5332EUR$5,950USD£4,649GBP
- Report
- May 2023
- 119 Pages
Global
From €4033EUR$4,500USD£3,516GBP
- Report
- June 2024
- 200 Pages
Global
From €7125EUR$7,950USD£6,211GBP
- Report
- January 2024
- 267 Pages
Japan
From €3361EUR$3,750USD£2,930GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1792EUR$2,000USD£1,563GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2689EUR$3,000USD£2,344GBP
- Report
- April 2023
- 114 Pages
Global
From €4257EUR$4,750USD£3,711GBP
- Report
- March 2023
- 147 Pages
Global
From €4435EUR$4,949USD£3,867GBP
- Report
- March 2025
- 142 Pages
Global
From €3584EUR$3,999USD£3,124GBP

Steatohepatitis drugs are used to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These drugs are used to reduce inflammation, improve liver function, and reduce the risk of cirrhosis and liver cancer. They can also help to reduce the risk of cardiovascular disease. Commonly used steatohepatitis drugs include vitamin E, pioglitazone, obeticholic acid, and elafibranor.
These drugs are part of the larger market of liver and kidney disorder drugs, which also includes drugs used to treat hepatitis, cirrhosis, and other liver and kidney diseases.
Some companies in the steatohepatitis drugs market include Gilead Sciences, Intercept Pharmaceuticals, Allergan, Novartis, and Merck. Show Less Read more